The Older Driver, Clinical Assessment and Injury Prevention
Arch Int Med 152:735-740, Underwood,M., 1992
Optic-Nerve Degeneration in Alzheimer's Disease
NEJM 315:485-487, Hinton,D.R.,et al, 1986
Oligoclonal IgG Bands in Cerebrospinal Fluid in Various Neurological Diseases
Ann Neurol 13:434-439, Chu,A.B.,et al, 1983
Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023
Brexpiprazole for the Treatment of Agitation and Aggression in Alzheimers Disease
JAMA Neurol 80:1272-1273, Ballard,C., 2023
"Noncognitive" Symptoms of Early Alzheimer Disease
Neurol 84:617-622, Masters, M.C.,et al, 2015
Assessment and Management of Behavioral and Psychological Symptoms of Dementia
BMJ 350:h369, Kales, H.C.,et al, 2015
Effect of Dextromethorphan-Quinidine on Agitation in Patients with Alzheimer Disease Dementia
JAMA 314:1242-1254, Cummings, J.L.,et al, 2015
Effect of Citalopram on Agitation in Alzheimer Disease The CitAD Randomized Clinical Trial
JAMA 311:682-691, Porsteinsson, A.P.,et al, 2014
Relapse Risk after Discontinuation of Risperidone in Alzheimers Disease
NEJM 367:1497-1507, Devanand, D.P.,et al, 2012
Alzheimers Disease
BMJ 338:467-471, Burns,A. &Iliffe,S., 2009
Fully-Automated Quantification of Regional Brain Volumes for Improved Detection of Focal Atrophy in Alzheimers Disease
AJNR 30:578-580, Brewer, J.B.,et al, 2009
Risperidone, Haloperidol, and Placebo in the Treatment of Aggressive Challenging Behaviour in Patients With Intellectual Disability: A Randomised Controlled Trial
Lancet 371:57-63,9, Tyrer,P.,et al, 2008
Donepezil for the Treatment of Agitation in Alzheimers Disease
NEJM 357:1382-1392,1441, Howard,R.J.,et al, 2007
Effect of Enhanced Psychosocial Care on Antipsychotic Use in Nursing Home Residents with Severe Dementia; Cluster Randomised Trial
BMJ 332:756-758,741, Fossey,J.,et al, 2006
Behavioral Effects of Memantine in Alzheimer Disease Patients Receiving Donepezil Treatment
Neurol 67:57-63, Cummings,J.L.,et al, 2006
Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimers Disease
NEJM 355:1525-1538,1604, Schneider,L.S.,et al, 2006
Pharmacological treatment of Neuropsychiatric Symptoms of Dementia
JAMA 293:596-608, Sink,K.M.,et al, 2005
The Efficacy of Donepezil in the Treatment of Neuropsychiatric Symptoms in Alzheimer Disease
Neurol 63:214-219,200, Holmes,C.,et al, 2004
Neuro-Ophthalmic Findings in the Visual Variant of Alzheimers Disease
Ophthalmology 111:376-381, Lee,A.G. &Martin,C.O., 2004
Alzheimer Disease
JAMA 287:2335-2338, Cummings,J.L. &Cole,G., 2002
Donepezil Therapy in Clinical Practice, A Randomized Crossover Study
Arch Neurol 57:94-99, Greenberg,S.M.,et al, 2000
Relation Between Cholinesterase Inhibitor and Pisa Syndrome
Lancet 355:2222, Kwak,Y.T. et al, 2000
Treatment of Agitation in AD
Neurol 55:1271-1278,1247, Teri,L.,et al, 2000
Medial Temporal Lobe Atrophy on MRI in Dementia with Lewy Bodies
Neurol 52:1153-1158, Barber,R.,et al, 1999
Treatment of Alzheimer's Disease
NEJM 341:1670-1679, Mayeux,R.&Sano,M, 1999
Functional Magnetic Resonance Imaging in Neuropsychiatry
BMJ 319:1551-1554, Longworth,C.,et al, 1999
Early Dopaminergic Drug-Induced Hallucinations in Parkinsonian Patients
Neurol 51:811-814, Goetz,C.G.,et al, 1998
Clinical Features and Pharmacologic Treatment of Behavioral Symptoms of Alzheimer's Disease
Neurol 48 (Suppl 6) :S17-S24997., Borson,S.&Raskind,M.A., 1997
Diagnosis and Treatment of Alzheimer Disease and Related Disorders
JAMA 278:1363-1371, Small,G.W.,et al, 1997
Lewy Body Disease and Dementia
Arch Int Med 156:487-493, Kalra,S.,et al, 1996
Low Body Weight in Alzheimer's Disease is Associated with Mesial Temporal Cortex Atrophy
Neurol 46:1585-1591, Grundman,M.,et al, 1996
Management of the Behavioral Manifestations of Dementia
Arch Int Med 155:250-260, Yeager,B.F.,et al, 1995
Rapidly Progressing Atrophy of Medial Temporal Lobe in Alzheimer's Disease
Lancet 343:829-830, Jobst,K.A.,et al, 1994
Phenotype of Chromosome 14-Linked Familial Alzheimer's Disease in a Large Kindred
Ann Neurol 36:368-378, Lampe,T.H.,et al, 1994
Growth Factors:Potential Therapeutic Applications in Neurology
JNNP 54:1445-1450, Drago,J.,et al, 1994
Murder, Insanity, and Medical Expert Witnesses
ARch Neurol 49:608-611, Ciccone,J.R., 1992
Detection in Life of Confirmed Alzheimer's Disease, Medial Temporal Lobe Atrophy by Computed Tomography
Lancet 340:1179-1183, Jobst,K.A.,et al, 1992
Cumulative Risks of Developing Extrapyramidal Signs, Psychosis, or Myoclonus in the Course of Alzheimer's Disease
Arch Neurol 48:1141-1143, Chen,J.,et al, 1991
A Pilot Study of Haloperidol Treatment of Psychosis and Behavioral Disturbance in Alzheimer's Disease
Arch Neurol 46:854-857, Devanand,D.P.,et al, 1989
Psychotic Symptoms in Alzheimer's Disease
Editorial, Lancet 2:1193-11941989., , 1989
The Psychiatric Symptoms of Alzheimer's Disease
J Am Geriatr Soc 36:7-12, Merriam,A.E.,et al, 1988
Genetic Linkage in Neurologic Diseases
Editorial, NEJM 316:1018-10201987., Martin,J.B., 1987
Predictors of Disease Course in Patients with Probable Alzheimer's Disease
Neurol 37:1649-1653, Stern,Y.,et al, 1987
The Role of Glutamate in Neurotransmission & in Neurologic Disease
Arch Neurol 43:1058-1063, Greenamyre,J.T., 1986
Alzheimer's Disease, Parkinson's Disease, & Motoneurone Disease:Abiotropic Interaction Between Ageing & Environment
Lancet 2:1067-1068, Calne,D.B.,et al, 1986
The Human Kluver-Bucy Syndrome
Neurol 33:1141-1145, Lilly,R.,et al, 1983
Capgras Syndrome:A Reduplicative Phenomenon
Neurol 29:334-339, Alexander,M.P.,et al, 1979
Neuro CPC of MGH
Glioblastoma Multiforme, NEJM 262:413-4161960., , 1960